Unique ID issued by UMIN | UMIN000035193 |
---|---|
Receipt number | R000040066 |
Scientific Title | Efficacy of IOP reduction and safety of Eybelis ophthalmic solution 0.002% switched from Prostaglandin analog. |
Date of disclosure of the study information | 2018/12/10 |
Last modified on | 2023/06/15 09:25:41 |
Efficacy of IOP reduction and safety of Eybelis ophthalmic solution 0.002% switched from Prostaglandin analog.
Efficacy of IOP reduction and safety of Eybelis ophthalmic solution 0.002% switched from Prostaglandin analog.
Efficacy of IOP reduction and safety of Eybelis ophthalmic solution 0.002% switched from Prostaglandin analog.
Efficacy of IOP reduction and safety of Eybelis ophthalmic solution 0.002% switched from Prostaglandin analog.
Japan |
glaucoma or ocular hypertension
Ophthalmology |
Others
NO
To investigate efficacy of IOP reduction and safety of Eybelis ophthalmic solution 0.002% switched from Prostaglandin analog in patients with glaucoma or ocular hypertension.
Safety,Efficacy
IOP reduction
Adverse event
Feeling of use
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Switching from Prostaglandin analog to Eybelis ophthalmic solution 0.002%
20 | years-old | <= |
Not applicable |
Male and Female
Patients with unilateral or bilateral primary open angle glaucoma or ocular hypertension
Patients with some deepening of upper eyelid sulcus after topical use of prostaglandin analogs
good adherence before the study initiation
Patients with aphakic eye or implanted IOL in the eye (history of cataract surgery), Patients with cataract surgery scheduled (within the last 6 months)
Patients with some corneal abnormality or other diseases which may interfere with accurate IOP measurement using Goldmann applanation tonometer
Patients with a history of corneal refractive surgery
Patients with active extraocular disease, inflammation or infection in the eye(s) or eyelid(s)
Patients with allergy to the ingredients used in the present study
Pregnant, lactating women or women who may be pregnant, and women who wish to be pregnant or can not conduct appropriate contraception during the study period
100
1st name | Kenji |
Middle name | |
Last name | Inoue |
Inouye Eye Hospital
Medical office
101-0062
4-3 Kanda Surugadai, Chiyoda-Tokyo, Japan
03-3295-0911
study@inouye-eye.or.jp
1st name | Kenji |
Middle name | |
Last name | Inoue |
Inouye Eye Hospital
Medical office
101-0062
4-3 Kanda Surugadai, Chiyoda-Tokyo, Japan
03-3295-0911
study@inouye-eye.or.jp
Inouye Eye Hospital
None
Self funding
Inouye Eye Hospital
4-3 Kanda Surugadai, Chiyoda-Tokyo, Japan
03-3295-0911
academy@inouye-eye.or.jp
NO
2018 | Year | 12 | Month | 10 | Day |
Unpublished
77
No longer recruiting
2018 | Year | 12 | Month | 05 | Day |
2018 | Year | 12 | Month | 03 | Day |
2018 | Year | 12 | Month | 07 | Day |
2023 | Year | 12 | Month | 07 | Day |
2018 | Year | 12 | Month | 10 | Day |
2023 | Year | 06 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040066
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |